CA2311903A1 - Multiple compartment container for medical solution - Google Patents
Multiple compartment container for medical solution Download PDFInfo
- Publication number
- CA2311903A1 CA2311903A1 CA002311903A CA2311903A CA2311903A1 CA 2311903 A1 CA2311903 A1 CA 2311903A1 CA 002311903 A CA002311903 A CA 002311903A CA 2311903 A CA2311903 A CA 2311903A CA 2311903 A1 CA2311903 A1 CA 2311903A1
- Authority
- CA
- Canada
- Prior art keywords
- glucose
- concentration
- calcium
- contents
- compartment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008155 medical solution Substances 0.000 title claims abstract description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 73
- 239000008103 glucose Substances 0.000 claims abstract description 73
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000011575 calcium Substances 0.000 claims abstract description 57
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 57
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 28
- 239000000243 solution Substances 0.000 claims abstract description 22
- 239000000385 dialysis solution Substances 0.000 claims abstract description 21
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 18
- 238000000502 dialysis Methods 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 238000003860 storage Methods 0.000 claims abstract description 7
- 230000007774 longterm Effects 0.000 claims abstract description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 18
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 22
- 239000011780 sodium chloride Substances 0.000 abstract description 11
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000001540 sodium lactate Substances 0.000 abstract description 4
- 229940005581 sodium lactate Drugs 0.000 abstract description 4
- 235000011088 sodium lactate Nutrition 0.000 abstract description 4
- 238000000108 ultra-filtration Methods 0.000 abstract description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 16
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940001447 lactate Drugs 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1656—Apparatus for preparing dialysates
- A61M1/1668—Details of containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/10—Bag-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
- A61J1/202—Separating means
- A61J1/2027—Separating means having frangible parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- External Artificial Organs (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Container for medical solution, particularly for peritoneal dialysis. A large compartment (10) contains the majority of the medical solution, such as sodium bicarbonate, sodium lactate and sodium chloride. In addition, a plurality of small compartments (14, 15) are provided which contain partial quantities of the medical solution which are not compatible for long term storage with the contents of the large compartment, such as calcium ions and glucose. By mixing the contents of the first (14) or second (15) of the small compartments with the contents of the large compartment (10), a solution is obtained having 1.5 % or 2.5 % glucose and 1.0 mM or 1.6 mM calcium. By mixing the contents of both the small compartments with the contents of the large compartment, a solution is obtained having 4.0 % glucose and 2.5 mM calcium. Due to the increased ultrafiltration at high glucose concentration, these medical solutions are calcium-neutral during use as peritoneal dialysis solutions.
Description
WO 99/27885 PCT/S1;98/02146 TITLE
Multiple compartment container for medical solution AREA OF INVENTION
The present invention relates to peritoneal dialysis, where a dialysis solution is present in a multiple compartment container provided with three or more compartments.
The invention relates particularly to such a container in IS which the dialysis solution contains bicarbonate as buffer, as well as glucose and calcium ions.
PRIOR ART
A container for peritoneal dialysis is disclosed in 2. The container contains conventional dialysis solution with lactate as buffer. The container thus comprises a first large compartment containing sodium lactate, sodium chloride, calcium chloride and magnesium chloride, as well as two small compartments containing glucose of high concentration and low pH. The container is sterilized in an autoclave with the solutions in situ in said compartments.
During use, either one or both of the compartments are connected to the large compartment by frangible pins whereby the dialysis solution contains a desired concentration of glucose, such as 1.50, 2.50 or 40. Using a three compartment container, it is possible to employ a single container for all three degrees of concentration, which reduces costs for logistics and storage.
Multiple compartment container for medical solution AREA OF INVENTION
The present invention relates to peritoneal dialysis, where a dialysis solution is present in a multiple compartment container provided with three or more compartments.
The invention relates particularly to such a container in IS which the dialysis solution contains bicarbonate as buffer, as well as glucose and calcium ions.
PRIOR ART
A container for peritoneal dialysis is disclosed in 2. The container contains conventional dialysis solution with lactate as buffer. The container thus comprises a first large compartment containing sodium lactate, sodium chloride, calcium chloride and magnesium chloride, as well as two small compartments containing glucose of high concentration and low pH. The container is sterilized in an autoclave with the solutions in situ in said compartments.
During use, either one or both of the compartments are connected to the large compartment by frangible pins whereby the dialysis solution contains a desired concentration of glucose, such as 1.50, 2.50 or 40. Using a three compartment container, it is possible to employ a single container for all three degrees of concentration, which reduces costs for logistics and storage.
3~ SUMMARY OF THE INVENTION
An object to the present invention is to adapt the container according to WO 97/05852 for such type of peritoneal dialysis in which the lactate buffer is entirely or partially exchanged for a buffer consisting of bicarbonate.
As is known, bicarbonate cannot, however, be combined with calcium or magnesium in the large compartment since this may lead to precipitation of, for example, carbonates during long term storage or at high pH. Accordingly, bicarbonate and calcium/magnesium must be separated until shortly before use.
One option would be to include calcium in' the small compartments containing glucose and bicarbonate in the large compartment. Glucose and calcium/magnesium are largely compatible, i.e. they do not precipitate. However, the divalent ions catalyse glucose decomposition to a certain extent. During mixing of the contents of the small compartment with the contents of the large compartment shortly before use, the risk of .precipitation of carbonates is low since the pH-value of the entire solution is maintained well below pH = 7.4.
A conventional peritoneal dialysis solution has a calcium ion concentration of 1.75 mM (mmol/1) and a magnesium ion concentration between 0.25-0.50 mM. The buffer may be solely bicarbonate which thereby normally exists at a concentration of 30-40 mM or a combination of bicarbonate and lactate, for example 25 mM bicarbonate and 15 mM lactate.
In the following, only calcium ions will be considered since they are of the greatest clinical significance, although the principles of the invention is, of. course, equally applicable to magnesium ions.
If the above solution were, however, to be used in a three compartment container of the type which is described in WO 97/05852, a problem arises if the calcium ions are included in the small compartments in one and the same concentration.
When the contents of one of the small compartments are mixed with the contents of the large compartment, a concentration of 1:5o glucose and, for example, 1.75 mM calcium is created, which is regulated by the quantity of glucose and the concentration of calcium in the first small compartment. If the contents of the second small compartment are mixed with the contents of the large compartment, a concentration of 2.50 glucose and 1.75 mM calcium results, which is regulated by the quantity of glucose and the concentration of calcium in the second small compartment. If, however, the third -glucose concentration of 4% is to be obtained, the contents of both the first and the second small compartments are mixed with the contents of the large compartment, whereby a glucose concentration of 4o is obtained, but the calcium concentration becomes too great, in this case about 3.5 mM. It therefore does not seem to be possible to provide a three compartment container of this type offering the possibility of three different glucose concentrations, since the calcium concentration will be too high in the presence of the highest glucose concentration. It would be neccesary to expand the concept to a four compartment container, which, however, might result in new problems of safety.
IS A further object of the present invention is to propose a three compartment container of the above-mentioned type in which the above-mentioned problem is solved.
The problematic issues with calcium for peritoneal dialysis, as well as for haemodialysis, are complicated since dialysis patients normally eat calcium carbonate to bind phosphate which is present in food. A portion of the calcium carbonate which is consumed together with food is absorbed in the intestinal tract and increases the calcium concentration in the blood. At the same time, the calcium carbonate binds phosphate so that the phosphate load on the patient is reduced. Phosphate is a molecule which is difficult to remove from the body via dialysis since it does not pass easily through membranes, whether they be synthetic membranes or peritoneal membranes.
The calcium concentration in the peritoneal dialysis solution which is generally recommended today is 1.75 mM. This would seem to be a suitable compromise which corresponds to the normal physiological concentration of free calcium in blood, since calcium is present in blood both freely as well as bound to protein, particularly albumin. If the calcium concentration in the patient is increased, a removal of calcium takes place, whereas if the concentration is too low, calcium is supplied to the body.
WO. 99/27885 PCT/S 698/02146 Should a surplus of calcium arise, hypercalciemia, the following symptoms, among others, result: vomiting, dizziness, reduced muscle function, ECG-disorders and necrosis calcification.
Hypercalciemia is usually rectified by t:he patient avoiding consumption of calcium carbonate for several days, whereupon the calcium concentration quickly reduces.
On the other hand, hypocalciemia results in i.a. the following symptoms: cramps, hyper-reflexes, spasms, ECG
changes and hyperparatyroidism.
Hypocalciemia is normally counteracted by increased intake of calcium carbonate, while the calcium concentration in the dialysis solution is normally kept constant.
It is recognized that the problematics with calcium are difficult since the above-mentioned symptoms are difficult to diagnose.
More recently, it has been proposed to further reduce the calcium concentration in dialysis solution to 1.35, 1.25 or even 1.0 mM. The reason is that the oral intake of calcium carbonate can thereby be increased and further reduce the phosphate charge on the patient. The risk for hypocalciemia increases therewith and increased awareness for diagnosis and treatment is necessary.
Earlier trials have shown that the transport of calcium ions across the peritoneal membrane is affected by the glucose concentration in the peritoneal dialysis solution. This effect is, however, rarely discussed.
According to the present invention, however, this discovery is used to solve the above-mentioned problem in a three compartment container of the type which is described in WO 97/05852 to thereby adapt this container to a buffer comprising bicarbonate.
Our experiments with simulations of calcium transport across the peritoneal membrane indicate the following unexpected results. If a peritoneal dialysis solution is to be neutral (in- and outflow the same) with regard to the calcium transport during a four hour period, it should comprise about 1.2 mM calcium at 1.5o glucose, about 1.6 mM at 2.5% glucose and, finally, about 2.3 mM calcium at 4.Oo glucose, i.e. the calcium concentration should be substantially proportional to the glucose concentration in the final solution.
This can be achieved in a three compartment container by 5 means of calcium being present in substantially the same concentration in the two small glucose compartments. The final glucose concentration in the mixed solution is determined by the volume of the small compartments since the glucose concentration is identical in the small glucose compartments, for example 50%. This results in that the calcium concentration will always remain proportional to the glucose concentration. The higher the glucose concentration (greater volume), the more ultrafiltration and thus also higher calcium concentration in the mixed solution. The calcium concentration is may in that respect be selected so that the patient either has a net loss, net gain or neutral calcium balance irrespective of the ultra- filtration and the glucose concentration.
A further object in the present invention is to provide a three compartment container of the above-mentioned type with bicarbonate in the large compartment and glucose together with calcium in the two small compartments, whereby the increase in the calcium concentration at the highest glucose concentration results in better calcium control than previously. This invention is completely different from previously known methods in which the same calcium concentration has always been used irrespective of the glucose concentration.
By using a peritoneal dialysis solution in which the calcium concentration is proportional to the glucose concentration, it is possible to use one and the same solution in the small compartments, i.e. the equipment which is used to fill the three compartment container need only produce solutions having two different compositions, one for the large compartment and one for the two small compartments. In this manner, the manufacturing costs are reduced.
Thus, there is provided according to the invention a container containing a medical solution, particularly for peritoneal dialysis, consisting of a large compartment having a volume which is sufficiently large to contain the finally W0,99/27885 PCT/SE98/02146 prepared medical solution, and at least two small compartments which contain partial quantities of the medical solution which are incompatible for long term storage with the contents of the large compartment. The large compartment comprises bicarbonate ions and the small compartments comprises glucose and calcium ions.
According to the invention, it is an advantage if the glucose concentration is substantially proportional to the calcium ion concentration in the finally prepared medical solution.
To obtain such proportional concentration, the two small compartments may comprises solutions having the same concentration of glucose and calcium, though having different volumes, or the first of the small compartments contains IS glucose and calcium ions with such a concentration that the glucose concentration when mixing the contents of said first small compartment with the contents of the large comparment obtains a first predetermined value, such as 1.50, and the calcium ion concentration obtains a second predetermined value, such as 1.0 mM, while the second of the small compartments contains glucose and calcium ions having such a concentration so that the glucose concentration in the finally prepared solution when mixing the contents of said second small compartment with the contents of the large comparment obtains a third predetermined value, such as 2.5%, and the calcium ion concentration obtains a fourth predetermined value, such as 1.6 mM, and finally the contents of the first and the second of the small compartments may be mixed with the contents of the large compartment to obtain a finally prepared solution with higher concentrations of glucose and calcium ions, such as 4% glucose concentration and 2.5 mM calcium.
The small compartments may further comprise magnesium ions, for example in a concentration such that the resulting concentration in the finally prepared medical solution is about 0.25-0.75 mM.
The invention also relates to a method for preparing a medical solution, particularly for peritoneal dialysis, in a container consisting of a first large compartment having a volume which is sufficiently large to contain the finally prepared medical solution, and a plurality of small compartments which contain partial quantities of the medical solution which are not compatible for long term storage with the contents of the large compartment. The large compartment comprises bicarbonate ions and the small compartments comprise glucose and calcium ions. The contents of one or more of the small compartments are mixed with the contents of the large compartment to produce a medical solution in which the concentration of glucose is substantially proportional to the concentration of calcium ions.
Finally, the invention also relates to a use of a container for preparation of a peritoneal dialysis solution in which the concentrations of glucose and calcium ions are substantially IS proportional.
BRIEF DESCRIPTION OF THE DRAWINGS
Further objects, problems, solutions and features will be apparent from the following detailed description of the invention with reference to the drawings describing several embodiments of the invention.
Fig. 1 is a plan view of a container which may be used in the present invention.
Figs. 2, 3 and 4 are computer-simulated diagrams which show the calcium balance across the peritoneal membrane.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
Fig. 1 discloses a three compartment container which may be used in the present invention. The container 1 is of the type which is sealed at both ends with weld seams 20 and 21. The container is divided into a large compartment 10 and two small compartments 14 and 15 by weld seams 11, 12 and 13.
The small compartment 14 and/or 15 may communicate with the large compartment 10 by means of frangible pins 18, 19 which are normally sealed but can be manually opened. When the frangible pin 18 and/or 19 is opened, the contents in the compartments 14 and/or 15 flow down into the large compartment 10 and mix with the contents therein.
WO~ 99/27885 PCT/SE98/02146 During manufacture of the container, suitable solution is supplied to the various compartments 10, 7_4 and 15 via inlet tubes 16, 17 and 22 extending through the weld seams 20 and 21. A sample and/or infusion port 23 extending through the weld seam 21 permits sampling from, and infusion to, the compartment 10.
The solution in the compartment 10 is supplied to a patient via a conduit 24. The container is placed on a stand by means of an opening 25 in the upper weld seam 20. The bag described so far is substantially identical to the one disclosed in WO 97/05852.
The container preferably has a size such that two litres of peritoneal dialysis solution are accommodated in the large compartment 10 in a ready-mixed state. Larger or smaller containers are of course feasible according to the invention.
We have studied the transport of calcium ions across the peritoneal membrane as a function of time, during treatment with a peritoneal dialysis solution comprising glucose as well as different concentrations of calcium ions. Figs. 2, 3 and 4 show the results for glucose concentrations of 1.50, 2.5o and 40, respectively. It is apparent that the calcium transport is not only dependent on the concentration gradient across the peritoneal membrane, but also ultrafiltration contributes. A
normal CAPD-treatment requires that the patient carries a PD-solution for four hours (240 minutes) and then exchanges it for a fresh PD-solution. If such a PD-solution should result in zero transport of calcium across the peritoneal membrane during the 240 minute period, calcium concentrations of 1.2 mM, 1.6 mM and 2.3 mM respectively are required.
The calculations presuppose certain properties of i.a. the peritoneal membrane. We have concluded that a calcium concentration which is substantially proportional to the glucose concentration results in a substantially calcium-neutral treatment, i.e. the calcium transport across the peritoneal membrane will be substantially the same, independent of the selected glucose concentration.
In accordance with the present invention, the container 1 is to be used to prepare a peritoneal dialysis solution in WO~ 99/27885 PCT/SE98/02146 which the buffer consists of bicarbonate. Accordingly, the solutions in the various compartments may be the following.
The compartment 10 contains 1900 ml with the composition:
sodium bicarbonate 40 mM
sodium chloride 132 mM
Compartment 14 contains 100 ml of the composition:
glucose 30%
calcium chloride 20 mM
magnesium chloride 5 mM
sodium chloride 132 mM
Compartment 15 contains 100 ml of the composition:
glucose 50%
calcium chloride 33 mM
magnesium chloride 8 mM
sodium chloride 132 mM
By mixing the contents of compartment 14 and compartment 10, a peritoneal dialysis solution is obtained with the following composition:
glucose 1.50 calcium 1.0 mM
bicarbonate 38 mM
sodium 132 mM
magnesium 0.25 mM
Mixing the contents of compartment 15 and compartment 10 results in a dialysis solution having the composition:
W O. 99/27885 PCT/S E 98/02146 glucose 2.50 calcium 1.65 mM
bicarbonate 38 mM
sodium 132 mM
magnesium 0.4 mM
By mixing the contents of both compartments l4~and 15 with the contents of compartment 10, a dialysis solution is obtained having the followi ng composition:
glucose 4.0%
calcium 2.5 mM
bicarbonate 36 mM
sodium 132 mM
magnesium 0.6 mM
In a second example of the invention, the contents of each of the small compartments have the same composition according to the following:
EXAMPLE 2 ' Compartment 10 contains 1950 ml of the composition:
sodium bicarbonate 25 mM
sodium lactate 15 mM
sodium chloride 132 mM
Compartment 14 contains 60 ml of the composition:
glucose 500 calcium chloride 33 mM
magnesium chloride 8 mM
sodium chloride 132 mM
WO '99/27885 PCT/SE98/02146 Compartment 15 contains 100 ml of the composition:
glucose 500 calcium chloride 33 mM
magnesium chloride 8 mM
sodium chloride 132 mM
In a further alternative embodiment of the present invention, solutions are employed with the following compositions in the various compartments 10, 14 and 15.
Compartment 10 contains 1850 ml of the composition:
IS sodium bicarbonate 27 mM
sodium lactate 16 mM
sodium chloride 132 mM
Compartment 14 contains 150 ml of the composition:
glucose 200 calcium chloride 13 mM
magnesium chloride 3.2 mM
sodium chloride 132 mM
Compartment 15 contains 260 ml of the composition:
glucose 200 calcium chloride 12.5 mM
magnesium chloride 3.1 mM
sodium chloride 132 mM
Because of the effect of dilution, the calcium concentration will be somewhat lower than in the first two examples.
To avoid problems with high pH-values, the pH-value in the large compartment is normally adjusted to a pH = 7.2. The pH-value in the small compartments is normally low, about 3.0, in order to prevent glucose decomposition during autoclaving.
When a patient uses a container according to the present invention, he will experience a calcium inflow or outflow which is determined by the concentration of free calcium in the blood and the concentration of calcium in the finally prepared dialysis solution as well as the glucose concentration. In the case with the highest a1»~~.~P
concentration, the net effect will be approximately the same as with the two lower concentrations and the use of the container according to the invention is, therefore, easy and simple for the patient.
The invention has been described above with reference to preferred embodiments of the invention. A skilled person will recognize that further combinations are possible.
is Modifications which are appearant to a skilled person are intended to be incorporated within the scope of the invention.
The invention is limited only by the appended claims.
An object to the present invention is to adapt the container according to WO 97/05852 for such type of peritoneal dialysis in which the lactate buffer is entirely or partially exchanged for a buffer consisting of bicarbonate.
As is known, bicarbonate cannot, however, be combined with calcium or magnesium in the large compartment since this may lead to precipitation of, for example, carbonates during long term storage or at high pH. Accordingly, bicarbonate and calcium/magnesium must be separated until shortly before use.
One option would be to include calcium in' the small compartments containing glucose and bicarbonate in the large compartment. Glucose and calcium/magnesium are largely compatible, i.e. they do not precipitate. However, the divalent ions catalyse glucose decomposition to a certain extent. During mixing of the contents of the small compartment with the contents of the large compartment shortly before use, the risk of .precipitation of carbonates is low since the pH-value of the entire solution is maintained well below pH = 7.4.
A conventional peritoneal dialysis solution has a calcium ion concentration of 1.75 mM (mmol/1) and a magnesium ion concentration between 0.25-0.50 mM. The buffer may be solely bicarbonate which thereby normally exists at a concentration of 30-40 mM or a combination of bicarbonate and lactate, for example 25 mM bicarbonate and 15 mM lactate.
In the following, only calcium ions will be considered since they are of the greatest clinical significance, although the principles of the invention is, of. course, equally applicable to magnesium ions.
If the above solution were, however, to be used in a three compartment container of the type which is described in WO 97/05852, a problem arises if the calcium ions are included in the small compartments in one and the same concentration.
When the contents of one of the small compartments are mixed with the contents of the large compartment, a concentration of 1:5o glucose and, for example, 1.75 mM calcium is created, which is regulated by the quantity of glucose and the concentration of calcium in the first small compartment. If the contents of the second small compartment are mixed with the contents of the large compartment, a concentration of 2.50 glucose and 1.75 mM calcium results, which is regulated by the quantity of glucose and the concentration of calcium in the second small compartment. If, however, the third -glucose concentration of 4% is to be obtained, the contents of both the first and the second small compartments are mixed with the contents of the large compartment, whereby a glucose concentration of 4o is obtained, but the calcium concentration becomes too great, in this case about 3.5 mM. It therefore does not seem to be possible to provide a three compartment container of this type offering the possibility of three different glucose concentrations, since the calcium concentration will be too high in the presence of the highest glucose concentration. It would be neccesary to expand the concept to a four compartment container, which, however, might result in new problems of safety.
IS A further object of the present invention is to propose a three compartment container of the above-mentioned type in which the above-mentioned problem is solved.
The problematic issues with calcium for peritoneal dialysis, as well as for haemodialysis, are complicated since dialysis patients normally eat calcium carbonate to bind phosphate which is present in food. A portion of the calcium carbonate which is consumed together with food is absorbed in the intestinal tract and increases the calcium concentration in the blood. At the same time, the calcium carbonate binds phosphate so that the phosphate load on the patient is reduced. Phosphate is a molecule which is difficult to remove from the body via dialysis since it does not pass easily through membranes, whether they be synthetic membranes or peritoneal membranes.
The calcium concentration in the peritoneal dialysis solution which is generally recommended today is 1.75 mM. This would seem to be a suitable compromise which corresponds to the normal physiological concentration of free calcium in blood, since calcium is present in blood both freely as well as bound to protein, particularly albumin. If the calcium concentration in the patient is increased, a removal of calcium takes place, whereas if the concentration is too low, calcium is supplied to the body.
WO. 99/27885 PCT/S 698/02146 Should a surplus of calcium arise, hypercalciemia, the following symptoms, among others, result: vomiting, dizziness, reduced muscle function, ECG-disorders and necrosis calcification.
Hypercalciemia is usually rectified by t:he patient avoiding consumption of calcium carbonate for several days, whereupon the calcium concentration quickly reduces.
On the other hand, hypocalciemia results in i.a. the following symptoms: cramps, hyper-reflexes, spasms, ECG
changes and hyperparatyroidism.
Hypocalciemia is normally counteracted by increased intake of calcium carbonate, while the calcium concentration in the dialysis solution is normally kept constant.
It is recognized that the problematics with calcium are difficult since the above-mentioned symptoms are difficult to diagnose.
More recently, it has been proposed to further reduce the calcium concentration in dialysis solution to 1.35, 1.25 or even 1.0 mM. The reason is that the oral intake of calcium carbonate can thereby be increased and further reduce the phosphate charge on the patient. The risk for hypocalciemia increases therewith and increased awareness for diagnosis and treatment is necessary.
Earlier trials have shown that the transport of calcium ions across the peritoneal membrane is affected by the glucose concentration in the peritoneal dialysis solution. This effect is, however, rarely discussed.
According to the present invention, however, this discovery is used to solve the above-mentioned problem in a three compartment container of the type which is described in WO 97/05852 to thereby adapt this container to a buffer comprising bicarbonate.
Our experiments with simulations of calcium transport across the peritoneal membrane indicate the following unexpected results. If a peritoneal dialysis solution is to be neutral (in- and outflow the same) with regard to the calcium transport during a four hour period, it should comprise about 1.2 mM calcium at 1.5o glucose, about 1.6 mM at 2.5% glucose and, finally, about 2.3 mM calcium at 4.Oo glucose, i.e. the calcium concentration should be substantially proportional to the glucose concentration in the final solution.
This can be achieved in a three compartment container by 5 means of calcium being present in substantially the same concentration in the two small glucose compartments. The final glucose concentration in the mixed solution is determined by the volume of the small compartments since the glucose concentration is identical in the small glucose compartments, for example 50%. This results in that the calcium concentration will always remain proportional to the glucose concentration. The higher the glucose concentration (greater volume), the more ultrafiltration and thus also higher calcium concentration in the mixed solution. The calcium concentration is may in that respect be selected so that the patient either has a net loss, net gain or neutral calcium balance irrespective of the ultra- filtration and the glucose concentration.
A further object in the present invention is to provide a three compartment container of the above-mentioned type with bicarbonate in the large compartment and glucose together with calcium in the two small compartments, whereby the increase in the calcium concentration at the highest glucose concentration results in better calcium control than previously. This invention is completely different from previously known methods in which the same calcium concentration has always been used irrespective of the glucose concentration.
By using a peritoneal dialysis solution in which the calcium concentration is proportional to the glucose concentration, it is possible to use one and the same solution in the small compartments, i.e. the equipment which is used to fill the three compartment container need only produce solutions having two different compositions, one for the large compartment and one for the two small compartments. In this manner, the manufacturing costs are reduced.
Thus, there is provided according to the invention a container containing a medical solution, particularly for peritoneal dialysis, consisting of a large compartment having a volume which is sufficiently large to contain the finally W0,99/27885 PCT/SE98/02146 prepared medical solution, and at least two small compartments which contain partial quantities of the medical solution which are incompatible for long term storage with the contents of the large compartment. The large compartment comprises bicarbonate ions and the small compartments comprises glucose and calcium ions.
According to the invention, it is an advantage if the glucose concentration is substantially proportional to the calcium ion concentration in the finally prepared medical solution.
To obtain such proportional concentration, the two small compartments may comprises solutions having the same concentration of glucose and calcium, though having different volumes, or the first of the small compartments contains IS glucose and calcium ions with such a concentration that the glucose concentration when mixing the contents of said first small compartment with the contents of the large comparment obtains a first predetermined value, such as 1.50, and the calcium ion concentration obtains a second predetermined value, such as 1.0 mM, while the second of the small compartments contains glucose and calcium ions having such a concentration so that the glucose concentration in the finally prepared solution when mixing the contents of said second small compartment with the contents of the large comparment obtains a third predetermined value, such as 2.5%, and the calcium ion concentration obtains a fourth predetermined value, such as 1.6 mM, and finally the contents of the first and the second of the small compartments may be mixed with the contents of the large compartment to obtain a finally prepared solution with higher concentrations of glucose and calcium ions, such as 4% glucose concentration and 2.5 mM calcium.
The small compartments may further comprise magnesium ions, for example in a concentration such that the resulting concentration in the finally prepared medical solution is about 0.25-0.75 mM.
The invention also relates to a method for preparing a medical solution, particularly for peritoneal dialysis, in a container consisting of a first large compartment having a volume which is sufficiently large to contain the finally prepared medical solution, and a plurality of small compartments which contain partial quantities of the medical solution which are not compatible for long term storage with the contents of the large compartment. The large compartment comprises bicarbonate ions and the small compartments comprise glucose and calcium ions. The contents of one or more of the small compartments are mixed with the contents of the large compartment to produce a medical solution in which the concentration of glucose is substantially proportional to the concentration of calcium ions.
Finally, the invention also relates to a use of a container for preparation of a peritoneal dialysis solution in which the concentrations of glucose and calcium ions are substantially IS proportional.
BRIEF DESCRIPTION OF THE DRAWINGS
Further objects, problems, solutions and features will be apparent from the following detailed description of the invention with reference to the drawings describing several embodiments of the invention.
Fig. 1 is a plan view of a container which may be used in the present invention.
Figs. 2, 3 and 4 are computer-simulated diagrams which show the calcium balance across the peritoneal membrane.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
Fig. 1 discloses a three compartment container which may be used in the present invention. The container 1 is of the type which is sealed at both ends with weld seams 20 and 21. The container is divided into a large compartment 10 and two small compartments 14 and 15 by weld seams 11, 12 and 13.
The small compartment 14 and/or 15 may communicate with the large compartment 10 by means of frangible pins 18, 19 which are normally sealed but can be manually opened. When the frangible pin 18 and/or 19 is opened, the contents in the compartments 14 and/or 15 flow down into the large compartment 10 and mix with the contents therein.
WO~ 99/27885 PCT/SE98/02146 During manufacture of the container, suitable solution is supplied to the various compartments 10, 7_4 and 15 via inlet tubes 16, 17 and 22 extending through the weld seams 20 and 21. A sample and/or infusion port 23 extending through the weld seam 21 permits sampling from, and infusion to, the compartment 10.
The solution in the compartment 10 is supplied to a patient via a conduit 24. The container is placed on a stand by means of an opening 25 in the upper weld seam 20. The bag described so far is substantially identical to the one disclosed in WO 97/05852.
The container preferably has a size such that two litres of peritoneal dialysis solution are accommodated in the large compartment 10 in a ready-mixed state. Larger or smaller containers are of course feasible according to the invention.
We have studied the transport of calcium ions across the peritoneal membrane as a function of time, during treatment with a peritoneal dialysis solution comprising glucose as well as different concentrations of calcium ions. Figs. 2, 3 and 4 show the results for glucose concentrations of 1.50, 2.5o and 40, respectively. It is apparent that the calcium transport is not only dependent on the concentration gradient across the peritoneal membrane, but also ultrafiltration contributes. A
normal CAPD-treatment requires that the patient carries a PD-solution for four hours (240 minutes) and then exchanges it for a fresh PD-solution. If such a PD-solution should result in zero transport of calcium across the peritoneal membrane during the 240 minute period, calcium concentrations of 1.2 mM, 1.6 mM and 2.3 mM respectively are required.
The calculations presuppose certain properties of i.a. the peritoneal membrane. We have concluded that a calcium concentration which is substantially proportional to the glucose concentration results in a substantially calcium-neutral treatment, i.e. the calcium transport across the peritoneal membrane will be substantially the same, independent of the selected glucose concentration.
In accordance with the present invention, the container 1 is to be used to prepare a peritoneal dialysis solution in WO~ 99/27885 PCT/SE98/02146 which the buffer consists of bicarbonate. Accordingly, the solutions in the various compartments may be the following.
The compartment 10 contains 1900 ml with the composition:
sodium bicarbonate 40 mM
sodium chloride 132 mM
Compartment 14 contains 100 ml of the composition:
glucose 30%
calcium chloride 20 mM
magnesium chloride 5 mM
sodium chloride 132 mM
Compartment 15 contains 100 ml of the composition:
glucose 50%
calcium chloride 33 mM
magnesium chloride 8 mM
sodium chloride 132 mM
By mixing the contents of compartment 14 and compartment 10, a peritoneal dialysis solution is obtained with the following composition:
glucose 1.50 calcium 1.0 mM
bicarbonate 38 mM
sodium 132 mM
magnesium 0.25 mM
Mixing the contents of compartment 15 and compartment 10 results in a dialysis solution having the composition:
W O. 99/27885 PCT/S E 98/02146 glucose 2.50 calcium 1.65 mM
bicarbonate 38 mM
sodium 132 mM
magnesium 0.4 mM
By mixing the contents of both compartments l4~and 15 with the contents of compartment 10, a dialysis solution is obtained having the followi ng composition:
glucose 4.0%
calcium 2.5 mM
bicarbonate 36 mM
sodium 132 mM
magnesium 0.6 mM
In a second example of the invention, the contents of each of the small compartments have the same composition according to the following:
EXAMPLE 2 ' Compartment 10 contains 1950 ml of the composition:
sodium bicarbonate 25 mM
sodium lactate 15 mM
sodium chloride 132 mM
Compartment 14 contains 60 ml of the composition:
glucose 500 calcium chloride 33 mM
magnesium chloride 8 mM
sodium chloride 132 mM
WO '99/27885 PCT/SE98/02146 Compartment 15 contains 100 ml of the composition:
glucose 500 calcium chloride 33 mM
magnesium chloride 8 mM
sodium chloride 132 mM
In a further alternative embodiment of the present invention, solutions are employed with the following compositions in the various compartments 10, 14 and 15.
Compartment 10 contains 1850 ml of the composition:
IS sodium bicarbonate 27 mM
sodium lactate 16 mM
sodium chloride 132 mM
Compartment 14 contains 150 ml of the composition:
glucose 200 calcium chloride 13 mM
magnesium chloride 3.2 mM
sodium chloride 132 mM
Compartment 15 contains 260 ml of the composition:
glucose 200 calcium chloride 12.5 mM
magnesium chloride 3.1 mM
sodium chloride 132 mM
Because of the effect of dilution, the calcium concentration will be somewhat lower than in the first two examples.
To avoid problems with high pH-values, the pH-value in the large compartment is normally adjusted to a pH = 7.2. The pH-value in the small compartments is normally low, about 3.0, in order to prevent glucose decomposition during autoclaving.
When a patient uses a container according to the present invention, he will experience a calcium inflow or outflow which is determined by the concentration of free calcium in the blood and the concentration of calcium in the finally prepared dialysis solution as well as the glucose concentration. In the case with the highest a1»~~.~P
concentration, the net effect will be approximately the same as with the two lower concentrations and the use of the container according to the invention is, therefore, easy and simple for the patient.
The invention has been described above with reference to preferred embodiments of the invention. A skilled person will recognize that further combinations are possible.
is Modifications which are appearant to a skilled person are intended to be incorporated within the scope of the invention.
The invention is limited only by the appended claims.
Claims (7)
1. Container containing a medical solution, particularly for peritoneal dialysis, consisting of a large compartment (10) having a volume which is sufficiently large to contain the finally prepared medical solution, and at least two small compartments (14, 15) which contain partial quantities of the medical solution which are incompatible for long term storage with the contents of the large compartment, characterized in that the large compartment (10) comprises bicarbonate ions and the small compartments (14, 15) comprises glucose and calcium ions.
2. Container according to claim 1, characterized in that the glucose concentration is substantially proportional to the calcium ion concentration in the finally prepared medical solution.
3. Container according to claim 2, characterized in that the small compartments (14, 15) comprises solutions having the same concentration of glucose and calcium, though having different volumes.
4. Container according to claim 1, characterized in that a first (14) of the small compartments contains glucose and calcium ions with such a concentration that the glucose concentration when mixing the contents of said first small compartment with the contents of the large comparment obtains a first predetermined value, such as 1.5%, and the calcium ion concentration obtains a second predetermined value, such as 1.0 mM, a second (15) of the small compartments contains glucose and calcium ions having such a concentration that the glucose concentration in the finally prepared solution when mixing the contents of said second small compartment with the contents of the large comparment obtains a third predetermined value, such as 2.5%, and the calcium ion concentration obtains a fourth predetermined value, such as 1.6 mM, and the contents of the first (14) and the second (15) of the small compartments may be mixed with the contents of the large compartment (10) to obtain a finally prepared solution with higher concentrations of glucose and calcium ions, such as 4% glucose concentration and 2.5 mM calcium.
5. Container according to any one of the preceding claims, characterized in that the small compartments (14, 15) further comprises magnesium ions, for example in a concentration such that the resulting concentration in the finally prepared medical solution is about 0.25-0.75 mM.
6. Method for preparing a medical solution, particularly for peritoneal dialysis, in a container consisting of a first large compartment having a volume which is sufficiently large to contain the finally prepared medical solution, and a plurality of small compartments which contain partial quantities of the medical solution which are not compatible for long term storage with the contents of the large compartment, characterized in that the large compartment comprises bicarbonate ions and the small compartments comprise glucose and calcium ions, and in that the contents of one or more of the small compartments are mixed with the contents of the large compartment to produce a medical solution in which the concentration of glucose is substantially proportional to the concentration of calcium ions.
7. Use of a container according to any one of claims 1-5 for preparation of a peritoneal dialysis solution in which the concentrations of glucose and calcium ions are substantially proportional.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704386-3 | 1997-11-28 | ||
| SE9704386A SE512349C2 (en) | 1997-11-28 | 1997-11-28 | Multi-chamber container for medical solution, procedure for preparation of medical solution for peritoneal dialysis and use of such container for preparation of medical solution |
| PCT/SE1998/002146 WO1999027885A1 (en) | 1997-11-28 | 1998-11-27 | Multiple compartment container for medical solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2311903A1 true CA2311903A1 (en) | 1999-06-10 |
Family
ID=20409165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002311903A Abandoned CA2311903A1 (en) | 1997-11-28 | 1998-11-27 | Multiple compartment container for medical solution |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1035823A1 (en) |
| JP (1) | JP2001524353A (en) |
| KR (1) | KR20010032191A (en) |
| CN (1) | CN1280481A (en) |
| AU (1) | AU742793B2 (en) |
| BR (1) | BR9815055A (en) |
| CA (1) | CA2311903A1 (en) |
| SE (1) | SE512349C2 (en) |
| WO (1) | WO1999027885A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0716607B1 (en) | 1994-07-01 | 2002-08-28 | Baxter International Inc. | Biochemically balanced peritoneal dialysis solutions |
| JP3060133U (en) * | 1997-10-27 | 1999-07-30 | 株式会社大塚製薬工場 | Eye perfusion / wash bag package |
| DE19912850B4 (en) † | 1999-03-22 | 2005-04-07 | Fresenius Medical Care Deutschland Gmbh | Solution, in particular for hemodialysis or peritoneal dialysis, and process for its preparation |
| SE9903331D0 (en) | 1999-09-16 | 1999-09-16 | Gambro Lundia Ab | Method and apparatus for sterilizing a heat sensitive fluid |
| WO2000057928A1 (en) | 1999-03-30 | 2000-10-05 | Gambro Lundia Ab | Method and apparatus for sterilising a heat sensitive fluid |
| US7122210B2 (en) † | 2002-01-11 | 2006-10-17 | Baxter International Inc. | Bicarbonate-based solutions for dialysis therapies |
| SE524530C2 (en) * | 2002-12-10 | 2004-08-24 | Gambro Lundia Ab | Solution useful in the manufacture of medicament for peritoneal dialysis e.g. continuous ambulatory peritoneal dialysis comprises acetylated or deacetylated amino sugar having specified pH |
| KR101142863B1 (en) | 2002-12-10 | 2012-05-21 | 프레제니우스 메디칼 케어 도이칠란드 게엠베하 | A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
| JP4361493B2 (en) * | 2002-12-10 | 2009-11-11 | ガンブロ・ルンディア・エービー | Method for preparing medical solutions for the manufacture of drugs for peritoneal dialysis |
| SE524531C2 (en) * | 2002-12-10 | 2004-08-24 | Gambro Lundia Ab | Solution useful in the manufacture of medicament for peritoneal dialysis e.g. continuous ambulatory peritoneal dialysis comprises acetylated or deacetylated amino sugar in specified amount |
| SE0301577L (en) | 2003-05-28 | 2004-11-29 | Gambro Lundia Ab | Low sodium solution |
| US9004761B2 (en) | 2006-05-01 | 2015-04-14 | Baxter International Inc. | Multiple chamber container with mistake proof administration system |
| DE102010039489A1 (en) * | 2010-08-18 | 2012-02-23 | Fresenius Medical Care Deutschland Gmbh | concentrate |
| DK3003358T3 (en) | 2013-06-07 | 2021-06-21 | Allena Pharmaceuticals Inc | COMPOSITIONS AND DIALYSIS DEVICES |
| DK178893B1 (en) * | 2015-07-05 | 2017-05-01 | Dorte Dyrsborg | Intravenous Bag |
| JP6578474B2 (en) * | 2015-09-03 | 2019-09-25 | レジメンキット株式会社 | Kit preparation and dose adjustment method |
| DE102018103937A1 (en) * | 2018-02-21 | 2019-08-22 | Fresenius Medical Care Deutschland Gmbh | Device containing dialysis solution or dialysis solution concentrate |
| EP3838246A4 (en) | 2018-08-17 | 2022-11-23 | Regimen Kit, Inc. | Drug management method for kit formulation requiring dose adjustment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH686778A5 (en) * | 1987-05-29 | 1996-06-28 | Vifor Medical Ag | Container for separate storage of active compounds and their subsequent mixing. |
| EP0442406B1 (en) * | 1990-02-14 | 1995-07-26 | Material Engineering Technology Laboratory, Inc. | Filled and sealed, self-contained mixing container |
-
1997
- 1997-11-28 SE SE9704386A patent/SE512349C2/en not_active IP Right Cessation
-
1998
- 1998-11-27 EP EP98959333A patent/EP1035823A1/en not_active Withdrawn
- 1998-11-27 JP JP2000522874A patent/JP2001524353A/en active Pending
- 1998-11-27 CN CN98811625A patent/CN1280481A/en active Pending
- 1998-11-27 BR BR9815055-3A patent/BR9815055A/en unknown
- 1998-11-27 CA CA002311903A patent/CA2311903A1/en not_active Abandoned
- 1998-11-27 WO PCT/SE1998/002146 patent/WO1999027885A1/en not_active Application Discontinuation
- 1998-11-27 KR KR1020007005381A patent/KR20010032191A/en not_active Application Discontinuation
- 1998-11-27 AU AU15153/99A patent/AU742793B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN1280481A (en) | 2001-01-17 |
| EP1035823A1 (en) | 2000-09-20 |
| WO1999027885A1 (en) | 1999-06-10 |
| KR20010032191A (en) | 2001-04-16 |
| AU742793B2 (en) | 2002-01-10 |
| JP2001524353A (en) | 2001-12-04 |
| SE9704386L (en) | 1999-05-29 |
| SE9704386D0 (en) | 1997-11-28 |
| AU1515399A (en) | 1999-06-16 |
| SE512349C2 (en) | 2000-03-06 |
| BR9815055A (en) | 2002-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU742793B2 (en) | Multiple compartment container for medical solution | |
| AU779950B2 (en) | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy | |
| TWI326597B (en) | Bicarbonate-based solutions for dialysis therapies | |
| US5092838A (en) | Histidine buffered peritoneal dialysis solution | |
| Walser et al. | Ion association. III. The effect of sulfate infusion on calcium excretion | |
| MXPA06014254A (en) | Bicarbonate-based peritoneal dialysis solutions. | |
| CA2566326C (en) | Peritoneal dialysis solution | |
| JP2001187111A (en) | Multichamber container | |
| WO1998010745A1 (en) | Batch quantity dialysate chemical formulations | |
| JP4135849B2 (en) | Solution, in particular a solution for hemodialysis or peritoneal dialysis and method for its preparation | |
| JP2009051850A (en) | Composition for treatment of renal failure comprising l-carnosine | |
| US20080149515A1 (en) | Container containing at least two solids and use thereof | |
| CN105640930A (en) | Iron metabolism-improving agent | |
| JPH08131542A (en) | Peritoneum dialysing liquid conditioning solution set | |
| MXPA04012299A (en) | A stable bicarbonate-based solution in a single container. | |
| JP2000245826A (en) | Neutral peritoneal dialysate | |
| EP0914147B1 (en) | Atrial natriuretic peptide (anp) as an additive to peritoneal dialysis solutions | |
| Havard | Symposium: Salt and Water [Abridged] Thiazide-Induced Antidiuresis in Diabetes Insipidus | |
| MXPA00005012A (en) | Multiple compartment container for medical solution | |
| Chebrolu et al. | Phosphorus-enriched hemodialysis for the treatment of patients with severe methanol intoxication | |
| CN101568334A (en) | Iron metabolism-improving agent | |
| Feriani et al. | Continuous ambulatory peritoneal dialysis with bicarbonate buffer-a pilot study | |
| JP2003088582A (en) | Peritoneal dialysate and storage vessel | |
| AU2008201009B2 (en) | Bicarbonate-based solutions for dialysis therapies | |
| Mayer | Diet and renal disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |